Touted as the largest amyotrophic lateral sclerosis (ALS) investigative effort to date, the Answer ALS research program has finished an initial technology infrastructure stage and is ready to embark on ... Read more

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Cytokinetics and Astellas Pharma‘s reldesemtiv for the treatment of amyotrophic lateral sclerosis (ALS), the companies announced. Reldesemtiv, ... Read more

Updated results from the CENTAUR Phase 2 trial show that Amylyx‘s investigational oral treatment, AMX0035, significantly slowed progression in treated amyotrophic lateral sclerosis (ALS) patients with rapidly advancing disease compared to those given a ... Read more

Mitsubishi Tanabe Pharma America (MTPA) and Soleo Health have entered into an agreement that will facilitate Soleo sharing real-world data about the use of MTPA’s Radicava (edaravone) in amyotrophic ... Read more

The U.S. Food and Drug Administration has agreed to expand Tiglutik, a liquid oral form of riluzole, to include giving it via a feeding tube to treat amyotrophic lateral ... Read more

MediciNova‘s experimental therapeutic ibudilast (MN-166) may be most effective for treating amyotrophic lateral sclerosis (ALS) in people with a shorter history of the disease, namely those diagnosed less than 18 months ... Read more

Researchers with Orion Corporation presented new data on levosimendan‘s mechanism of action, and potential biomarkers of amyotrophic lateral sclerosis (ALS) progression. The data were recently presented in four posters at ... Read more

A new ALS Association partnership with the ALS Investment Fund II seeks to raise $100 million in new funding to advance amyotrophic lateral sclerosis (ALS) therapy development. This second ... Read more

With so much recent publicity surrounding gene therapy, it’s no surprise that the topic was a major focus of the recent 2019 NORD Rare Diseases & Orphan Products Breakthrough ... Read more

Treatment with oral reldesemtiv appears to slow the deterioration of function — including breathing capacity and muscle strength — in amyotrophic lateral sclerosis (ALS) patients, regardless of whether or ... Read more